NCT00290017终止3 期
A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
Point Therapeutics195 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2006年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 400
- 试验地点
- 195
研究概览
简要总结
This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women age ≥18 years
- •Histologically or cytologically confirmed NSCLC (Recurrent, locally advanced or metastatic, inoperable NSCLC [Stage IIIB/IV]. Patients with Stage IIIB NSCLC must have a cytologically documented pleural effusion.)
- •Failed or relapsed after receiving a platinum-containing chemotherapy regimen as first-line therapy for advanced NSCLC
- •Measurable disease on computerized tomography (CT) scan
- •ECOG Performance Status of 0 or 1
- •Expected survival ≥12 weeks
- •Provide written informed consent
排除标准
- •More than 2 prior chemotherapy regimens
- •Progression of disease on prior pemetrexed treatment
- •Brain metastases (exception: patients who had a resection and/or completed a course of cranial irradiation, have no worsening CNS symptoms, and have discontinued all corticosteroids for that indication for at least 1 month)
- •Serum creatinine ≥2.0mg/dL or creatinine clearance <45mL/min
- •Absolute neutrophil count <1500/μL or platelets <100,000/μL
- •Any malignancy within 5 years immediately prior to the first dose of study medication (exception: basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix)
- •Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol
- •Patients who are within 28 days of chemotherapy, radiation therapy, immunotherapy, or investigational medication for NSCLC. Patients must have recovered from all of the side effects of treatment.
- •Pregnancy or lactation. Women of childbearing potential and non-vasectomized men must agree to use a barrier method of contraception during treatment.
研究者
研究点 (195)
Loading locations...
相似试验
招募中
3 期
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisActive Juvenile Psoriatic ArthritisNCT04804553Amgen60
已完成
3 期
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaUC (Urothelial Cancer)NCT03374488Incyte Corporation84
已完成
3 期
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque PsoriasisPsoriasisPsoriatic ArthritisNCT01690299Amgen250
招募中
3 期
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's DiseaseBehçet DiseaseNCT04528082Amgen60
已完成
3 期
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.Gastric CancerNCT01924533AstraZeneca525